Recently, ELIAS Animal Health announced new data on a chemo-immunotherapy approach using the ELIAS Cancer Immunotherapy (ECI®) to treat canine osteosarcoma that demonstrated improved outcomes. The analysis showed that combining the initial cytotoxic effects of chemotherapy with the targeted immune-mediated response stimulated by ECI® has the potential to enhance overall response and survival rates in canine cancer patients. In the study, 14 dogs received one dose of carboplatin followed by ECI® initiated 21 days later. This treatment group showed the best response, with a 1-year survival rate of 71% compared to 21% in 14 matched control dogs that received four doses of carboplatin only. See the data>>
An updated in-depth analysis of this combination approach with additional data will be presented at the 2025 Veterinary Cancer Society (VCS) Annual Conference in Salt Lake City, Utah. Jeffrey N Bryan, DVM, MS, PhD, DACVIM(O), who presented the first analysis at the 2025 American College of Veterinary Medicine (ACVIM) Forum, will present the updated analysis during a 25-minute oral presentation titled, “One-dose carboplatin followed by vaccine-enhanced adoptive cell therapy (ECI®) improves outcomes compared to four-dose carboplatin in dogs with osteosarcoma.” The presentation is scheduled during the Spotlight Research Session on Friday, September 26, 2025, at 10:00 AM Pacific Time. Dr. Bryan is a Professor of Oncology and Associate Director of the Ellis Fischel Cancer Center at the University of Missouri.
In March 2025, ECI® became the first USDA-approved product for the treatment of canine osteosarcoma. The immunotherapy harnesses the dog’s own immune system by combining an autologous vaccine with activated T cells to target cancer cells.
Veterinary professionals attending the VCS Annual Conference in September can learn more about the study and ECI® by visiting the ELIAS Animal Health booth.
About ELIAS Animal Health
ELIAS Animal Health is a medical biotechnology company focused on advancing a pipeline of immunotherapies, including an adoptive cell therapy and an oncolytic virotherapy, for the treatment of canine cancers. The company’s therapeutic pipeline offers the prospect of improved clinical outcomes and the potential for fundamentally changing the way cancer is treated. Learn more at www.eliasanimalhealth.com.
About ECI®
ECI® is an autologous prescription product (USDA Product Code 95A7.50) that has been evaluated in multiple clinical studies and is approved for veterinary use by the USDA Center for Veterinary Biologics. As an adoptive cell therapy, ECI® combines an autologous vaccine with cell therapy to target a patient’s unique cancer cells. This personalized approach can improve clinical outcomes and provide a better quality of life for canine patients. ECI® is available at more than 100 authorized treatment centers across the U.S. Learn more at www.eliasanimalhealth.com/elias-cancer-immunotherapy/.